Johnson & Johnson to purchase heart pump maker Abiomed for $16.6bn
Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The ... Read More
Hyloris Pharmaceuticals buys global rights to CRD-102 from Baker Institute
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) ... Read More
VisCardia wraps up VisONE heart failure pilot study
VisONE heart failure pilot study : Oregon-based medical device developer VisCardia has wrapped up its first-in-human study of the implantable VisONE system for medically refractory ... Read More
Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure
Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of ... Read More
Impulse Dynamics raises $80m to commercialize Optimizer Smart System
Impulse Dynamics, a US medical device company, has secured $80.25 million in a Series D financing round led by medical technology investor Amzak Health Investors ... Read More
Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in ... Read More